Loading...

Calidi Biotherapeutics, Inc.

CLDI•AMEX
Healthcare
Biotechnology
$1.00
$0.30(42.57%)

Calidi Biotherapeutics, Inc. (CLDI) Stock Overview

Explore Calidi Biotherapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.0/100

Key Financials

Market Cap31M
P/E Ratio-1.15
EPS (TTM)$-1.12
ROE6.36%
Fundamental Analysis

AI Price Forecasts

1 Week$0.33
1 Month$0.03
3 Months$3.31
1 Year Target$0.37

CLDI Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Calidi Biotherapeutics, Inc. (CLDI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 89.61, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.37.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.15 and a market capitalization of 31M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

89.61RSI (14)
0.06MACD
36.71ADX
Stats data is not available for CLDIStats details for CLDI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$2.00
Average$2.00
High$2.00

Company Profile

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

CEO

Eric E. Poma

Employees

28

Headquarters

4475 Executive Drive, San Diego, CA

Founded

2021

Frequently Asked Questions

;